NisinZ® P

Developed for: oral cavity squamous cell carcinoma
Investigated by: National Cancer Institute (NCI) · University of California, Los Angeles · University of California, San Francisco

today NCT06097468 · Ph 1/2

20242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT06097468	Feb 2024 → Mar 2028 expected	oral cavity squamous cell carcinoma	University of California, San Francisco	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NisinZ P	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06097468 ↗
Route	Oral	“Participants will ingest oral nisin once daily” NCT06097468 ↗